---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-257621"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:24:27.025825+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics discontinues solnerstotug, initiates strategic review for sale or wind-down

## Summary
- Board discontinues development of solnerstotug after review of pipeline and market conditions.
- Initiated comprehensive review of strategic alternatives, including sale, merger, licensing, or orderly wind-down.
- Workforce reduction planned to preserve cash; details to be disclosed separately.
- Small team retained to assist with strategic review, regulatory compliance, and orderly cessation of development.

## SEC filing metadata
- accession: 0001193125-25-257621
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312525257621/0001193125-25-257621-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312525257621/d201536d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-257621
- JSON: https://secwatch.observer/filing/0001193125-25-257621.json
- Plain text: https://secwatch.observer/filing/0001193125-25-257621.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.